A potent and selective Syk inhibitor
Related Products
Pro-drug Form(s)
18501R788 (sodium salt)
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

R406

Item No. 11422

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-2H-pyrido[3,2-b]-1,4-oxazin-3(4H)-one
CAS Number
841290-80-0
Molecular Formula
C22H23FN6O5
Formula Weight
470.5
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 0.5 mg/mlDMSO: 0.5 mg/ml
λmax
220, 278, 336 nm
SMILES
COC1=C(OC)C=C(NC2=NC(NC3=NC(NC(C(C)(C)O4)=O)=C4C=C3)=C(F)C=N2)C=C1OC
InChi Code
InChI=1S/C22H23FN6O5/c1-22(2)20(30)28-19-13(34-22)6-7-16(27-19)26-18-12(23)10-24-21(29-18)25-11-8-14(31-3)17(33-5)15(9-11)32-4/h6-10H,1-5H3,(H3,24,25,26,27,28,29,30)
InChi Key
NHHQJBCNYHBUSI-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $75

    Add

    5 mg

    $204

    Add

    10 mg

    $333

    Add

    25 mg

    $717

    Add
    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    R406 is a potent ATP-competitive inhibitor of spleen tyrosine kinase (Syk, Ki = 30 nM).1 Through this action, R406 blocks FcεRI-dependent mast cell activation (EC50 = 43 nM) and, at 3 μM, reduces the release of IL-10, -12, and -13 by immune complex-pulsed dendritic cells.1,2 R406 is orally available and can reduce immune complex-mediated inflammation.3 In cancers characterized by over-expression of Syk, R406 can prevent signaling downstream of Syk and induce apoptosis.4,5 R406 also inhibits Syk-dependent signaling through c-Jun N-terminal kinase in rheumatoid arthritis synoviocytes, suggesting a therapeutic intervention in this autoimmune disease.6,7

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Matsubara, S., Li, G., Takeda, K., et al. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am. J. Respir. Crit. Care Med. 173(1), 56-63 (2006).

    2. Matsubara, S., Koya, T., Takeda, K., et al. Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation. Am. J. Respir. Cell Mol. Biol. 34(4), 426-433 (2006).

    3. Braselmann, S., Taylor, V., Zhao, H., et al. R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation. J. Pharmacol. Exp. Ther. 319(3), 998-1008 (2006).

    4. Buchner, M., Fuchs, S., Prinz, G., et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res. 69(13), 5424-5432 (2009).

    5. Zhang, J., Benavente, C.A., McEvoy, J., et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481(7381), 329-334 (2012).

    6. Cha, H.S., Boyle, D.L., Inoue, T., et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J. Pharmacol. Exp. Ther. 317(2), 571-578 (2006).

    7. Singh, R., Masuda, E.S., and Payan, D.G. Discovery and development of spleen tyrosine kinase (SYK) inhibitors. J. Med. Chem. 55(8), 3614-3643 (2012).